Llerena-Ruiz Luis¹, Ortiz-Ordonez Andrea¹*, Núñez del Arco Luis¹, Fuenmayor-Duche Tatiana², Rosero-Caiza German³ and Bottani Laura⁴

¹Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, calle Diego de Robles s/n y Pampite, Quito, Ecuador
²Resident, Hospital de Especialidades Eugenio Espejo, Quito, Ecuador
³Universidad Católica del Ecuador, Ecuador
⁴Chief of Neurosurgery Department, Hospital de Especialidades Eugenio Espejo, Quito, Ecuador

*Corresponding Author: Ortiz-Ordonez Andrea, Neurosurgery Resident, Universidad San Francisco de Quito USFQ, Colegio de Ciencias de la Salud, calle Diego de Robles s/n y Pampite, Quito, Ecuador.

Received: May 31, 2021; Published: July 06, 2021

Citation: Ortiz-Ordonez Andrea., et al. “Racemose Neurocysticercosis: Medical and Surgical Treatment". Acta Scientific Clinical Case Reports 2.8 (2021): 13-19.

Abstract

Introduction: Neurocysticercosis is a parasitic infection of the central nervous system. The racemose variant tents to invade the subarachnoid space and it is considered malignant; It has increased morbidity and mortality and often shows a decreased response to medical treatment alone.

Case Reports: A 23‑year‑old male farmer with a 1 month of headache, seizures and mild language impairment. Imaging and serology confirmed racemose neurocysticercosis and responded well to medical treatment. A 48-year-old indigenous woman with long history of headache, seizures, worsening right hemiparesis, confusion, and incoherent speech. Imaging was compatible with racemose neurocysticercosis but did not respond to medical treatment. Due to worsening symptoms and lesions growth, surgery was performed. She had motor function improvement, but language and cognitive function remained altered.

Conclusion: In Racemose Neurocysticercosis, due to its fatal complications, medical treatment alone may have limited effect; an early surgical treatment can be a valid consideration in selected patients. However, previous neurological status may influence outcome.

Keywords: Neurocysticercosis; Racemose Neurocysticercosis; Surgical Treatment; Medical Treatment; Adult

Bibliography

1. Krupa Kristin., et al. “Racemose Neurocysticercosis”. Surgical Neurology International 1 (2016).
2. Leblanc Richard., et al. “Neurocysticercosis: Surgical and Medical Management with Praziquantel”. Neurosurgery 4 (1986): 419-427.
3. Uguña-Rosas Vilma A. “Cisticercosis Humana en el Ecuador”. Revista Killkana Salud y Bienestar 2 (2018): 35-42.
4. Almeida Marco Rafael Coral. “Epidemiological Transmission Patterns of Taenia Solium Cysticercosis in Endemic Areas: The Case of Ecuador”. (2015): 1-148.
5. Saini Arushi G., et al. “Racemose Neurocysticercosis”. Journal of Infection and Public Health 6 (2017): 884-885.
6. Mahale Rohan R., et al. “Extraparenchymal (Racemose) Neurocysticercosis and Its Multitude Manifestations: A Comprehensive Review”. Journal of Clinical Neurology 3 (2015): 203-211.
7. Rajshekhar Vedantam. “Surgical Management of Neurocysticercosis”. International Journal of Surgery 2 (2010): 100-104.
8. Zapata Carlos Hugo., et al. “Racemose Neurocysticercosis - Neuroimaging Guide the Diagnosis”. Biomédica 1 (2016): 26-32.
9. Carpio A., et al. “Cysticercosis and epilepsy: a critical review”. Epilepsia 10 (1998): 1025-1040.
10. Yang, Susan Y., et al. “Racemose Neurocysticercosis”. The American Journal of Tropical Medicine and Hygiene 4 (2020): 703-704.
11. Del Brutto Oscar H. “Neurocysticercosis: A Review”. The Scientific World Journal (2012).
12. Sierra M Marcin., et al. “Extraparenchymal neurocysticercosis: Demographic, clinicoradiological, and inflammatory features”. PLOS Neglected Tropical Diseases16 (2017): 1-16.
13. Chandrappa Anupama., et al. “A Rare Case of Enhancing Anterior Interhemispheric Racemose Neurocysticercosis with Foci of Calcification and Direct Parenchymal Extension”. Journal of Global Radiology1 (2018): 1-5.
14. Sanchez-Larsen Alvaro., et al. “Neurocisticercosis racemosa subaracnoidea gigante y ventricular: a propósito de un caso” [Giant racemose subarachnoid and intraventricular neurocysticercosis: A case report]”. Revista Argentina de Microbiologia3 (2015): 201-205.
15. Xiao Anqi., et al. “The Surgical Value of Neurocysticercosis: Analyzing 10 Patients in 5 Years”. Turkish Neurosurgery5 (2016): 744-749.
16. Rodriquez Roberta Diehl., et al. “Bruns’ Syndrome and Racemose Neurocysticercosis: A Case Report”. Revista Da Sociedade Brasileira de Medicina Tropical2 (2012): 269-271.
17. Carpio Arturo. “Neurocysticercosis: an update”. The Lancet12 (2002): 751-762.
18. Martinez Hector R., et al. “Medical and Surgical Treatment in Neurocysticercosis a Magnetic Resonance Study of 161 Cases”. Journal of the Neurological Sciences1 (1995): 25-34.
19. García Hector H., et al. “Current consensus guidelines for treatment of neurocysticercosis”. Clinical Microbiology Reviews4 (2002): 747-756.
20. Proaño Jefferson V., et al. “Medical Treatment for Neurocysticercosis Characterized by Giant Subarachnoid Cysts”. New England Journal of Medicine12 (2001): 879-885.
21. McClugage Samuel G., et al. “Treatment of racemose neurocysticercosis”. Surgical Neurology International168 (2017).
22. Fernández-Rodríguez Ricardo., et al. “Neurocisticercosis: Una Enfermedad Que No Debemos Olvidar”. Galicia Clínica3 (2017): 116.
23. Palacios-Ordóñez Enver Vantroi., et al. “Neurocisticercosis Racemosa”. Revista de La Sociedad Peruana de Medicina Interna1 (2019): 31-35.
24. Kumar Suresh., et al. “Giant racemose neurocysticercosis with mass effect: Unusual presentation”. Annals of Indian Academy Neurology3 (2013): 398-399.
25. Ballón Manrique Benigno. “Neurocisticercosis racemosa”. Revista Experiencia en Medicina1 (2017): 40-42.
26. Pamplona Jaime., et al. “A rare case of racemose neurocysticercosis and its complications. Case report”. The Neuroradiology Journal4 (2015): 418-420.
27. Citow Jonathan Stuart., et al. “Imaging features and surgery-related outcomes in intraventricular neurocysticercosis”. Neurosurgical Focus6 (2002): 6.

Copyright: © 2021 Ortiz-Ordonez Andrea., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.